Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Lin Chen, Simon N. Willis, Andrew H. Wei et al. · Molecular Cell · 2005 · 1.8K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x _L , but not Bcl-2, until displaced by BH3-only proteins

Simon N. Willis, Grant Dewson, Andrew H. Wei et al. · Genes & Development · 2005 · 1.2K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +17